Pharmaceutical company · GILD

Gilead Sciences
clinical trial
pipeline

Registry checked

Published

Sacituzumab Govitecan is linked to 16 distinct active studies, with 1 Phase 1, 7 Phase 2, 8 Phase 3. Lenacapavir is linked to 11 distinct active studies, with 4 Phase 2, 7 Phase 3.

Phase 2 study NCT05119907 in Solid Tumor lists estimated primary completion in October 2026. Phase 3 study NCT04639986 in Metastatic Breast Cancer lists estimated primary completion in December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

89active trials
as lead sponsor
  • Phase 120
  • Phase 233
  • Phase 333
  • Phase 41
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

1411 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved later

2028-06 (estimated)2028-12 (estimated)
Jun 2028Dec 2028

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

NCT07841977 · ClinicalTrials.gov
Recorded by ComplyRx
28 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-020000111
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070100122
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190100011
2026-10-200000111
2026-10-210000221
2026-10-220100121
2026-10-230000000
2026-10-241000011
2026-10-250000000
2026-10-261000011
2026-10-270000000
2026-10-281100021
2026-10-291000011
2026-10-300000000
Type totals440061411 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Sacituzumab Govitecan

Trodelvy

16
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 27
  • Phase 38
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced or Metastatic Solid Tumor · Advanced Solid Tumor · Endometrial Cancer
Next primary completion
Oct 2026 · estimated
Open drug

Lenacapavir

SUNLENCA · YEZTUGO

11
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 24
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
HIV Infections · HIV Pre-exposure Prophylaxis · HIV-1-infection
Next primary completion
Mar 2027 · estimated
Open drug

Anitocabtagene Autoleucel

Canonical investigational asset

5
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Multiple Myeloma · Newly Diagnosed Multiple Myeloma · Relapsed and Refractory Multiple Myeloma
Next primary completion
Dec 2026 · estimated
Open drug

Axicabtagene Ciloleucel

Canonical investigational asset

3
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded1
Studied condition
Autoimmune Diseases · High-risk Large B-cell Lymphoma (LBCL) · Relapsed/Refractory Follicular Lymphoma
Next primary completion
Not reported
Open drug

Seladelpar

LIVDELZI

3
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Primary Biliary Cholangitis · Primary Biliary Cirrhosis
Next primary completion
Not reported
Open drug

Denikitug

Canonical investigational asset

3
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Microsatellite Stable Colorectal Cancer · Advanced Solid Tumor · Esophageal Adenocarcinoma
Next primary completion
Not reported
Open drug

77 of 89 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 77 of 89 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Gilead Sciences trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Sacituzumab Govitecan

NCT05119907

Phase 2 · Active, not recruiting

Trial source and qualifications

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

5 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 12 Oct 2021 · actual
    Primary completion: Oct 2026 · estimated
    Study completion: Oct 2026 · estimated

    2021202220232024202520262027202820292030
    Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
    Sacituzumab Govitecan

    NCT04639986

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    Start clipped at the display horizon.

    2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 23 Nov 2020 · actual
      Primary completion: Dec 2026 · estimated
      Study completion: Dec 2026 · estimated

      2021202220232024202520262027202820292030
      iMMagine-1
      Anitocabtagene Autoleucel

      NCT05396885

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

      4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      4 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 15 Jul 2022 · actual
        Primary completion: Dec 2026 · estimated
        Study completion: Dec 2026 · estimated

        2021202220232024202520262027202820292030
        PALEKONA
        Tilpisertib Fosmecarbil

        NCT06029972

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

        • status flip · Recorded 2026-09-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 05 Dec 2023 · actual
        Primary completion: Jan 2027 · estimated
        Study completion: Feb 2028 · estimated

        2021202220232024202520262027202820292030
        ASCENT-04
        Sacituzumab Govitecan

        NCT05382286

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 25 Jul 2022 · actual
          Primary completion: Feb 2027 · estimated
          Study completion: Feb 2027 · estimated

          2021202220232024202520262027202820292030
          EVOKE-02
          Sacituzumab Govitecan

          NCT05186974

          Phase 2 · Active, not recruiting

          Trial source and qualifications

          Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

          • pc date moved · Recorded 2026-09-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 30 May 2022 · actual
          Primary completion: Mar 2027 · estimated
          Study completion: Mar 2027 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 42 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 19 actual primary completions, 0 untyped primary completions, 1 past estimates, 4 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          49

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology49 trials
          • Infectious Disease28 trials
          • Immunology & Inflammation4 trials
          • Gastroenterology & Hepatology3 trials
          • Neurology2 trials
          • Metabolic/Endocrine/Nutrition1 trials
          • Unmapped2 trials
          • Healthy volunteers0 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          M

          Merck

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 747 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Gilead Sciences. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          747 distinct registry candidates produced 747 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          702 scoped records have indexed enrichment and 45 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-10-31T23:58:24.164Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 289d4888f7580c6de3840b57c68d93a2e371663aa26cdab57b1d6c9e6a4bc7ff.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 747 mapped lead-sponsored clinical studies across all statuses. 702 have indexed enrichment, 45 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.